Vioxx ruling gives hope for payouts to British ‘victims’

Court says painkiller that doubles risk of heart attack is ‘not fit to be on market'

The popular painkiller Vioxx doubled the risk of a heart attack and was not fit to be on the market, a court ruled yesterday. In the world's first successful class action against the makers of the drug, judges found the subsidiary of the US pharmaceutical giant Merck had failed in its duty of care by not warning doctors about health risks.

The case raises awkward questions about why hundreds of British victims remain without compensation six years after health problems associated with Vioxx were uncovered. Yesterday's ruling in the Australian court follows a £2bn settlement in America over claims brought by 44,000 claimants who blamed the drug for cardiovascular problems.

Norman Lamb, the Liberal Democrat MP who has been campaigning for the British victims, said: "This is a very important and significant development. We have been trying to convince the company that it is ethically right and in their self-interests to do the decent thing and secure a settlement so British victims get a deal [similar to that] given to US victims."

But he said the company continued to deny liability. Mr Lamb also accused the UK government of failing to negotiate a settlement. "Ministers made promising noises then after a meeting between the Government and the company they weakened their position. I believe that the ministers came under pressure from the company and their own civil servants to shut up."

The ruling by the Federal Court in Melbourne is a major breakthrough for hundreds of Australians. The court ordered the company to pay £172,300 to Graeme Peterson, 59, who has been unable to work since a heart attack in 2003. At least 600 other Australians will now lodge compensation claims against Merck Sharpe and Dohme, which faces a bill of up to $300m, according to Peter Gordon, Mr Peterson's lawyer, whose law firm, Slater & Gordon, took on Mr Peterson's case for no fee.

Even more serious for Merck are the global implications: Vioxx was taken by more than 80 million people worldwide before it was recalled in 2004, and lawyers in several countries were awaiting the outcome of the Australian litigation. Mr Gordon said: "This ruling opens up an enormous liability in the UK and elsewhere. It's of enormous importance to potential victims in the UK. As long as people are able to demonstrate that had they known the full extent of the risks of taking Vioxx, they would have taken another painkiller, they should succeed in negligence cases."

Vioxx was hailed as a wonder drug for arthritis patients because, unlike traditional anti-inflammatories, it did not cause stomach problems. Merck mounted the biggest and most expensive recall in pharmaceutical history after a clinical study showed it increased heart attacks and strokes.

Mr Peterson, an occupational health and safety consultant, took Vioxx for more than four years. Yesterday, outside court, he produced a capsule, which he said he had kept as a reminder of a drug that had almost killed him. He said that while he welcomed the judgment, he would continue fighting for other victims. "There are people dying," he said. "I am one of the lucky ones. Sure it has affected my life, but I've still got my life. How many other people out there haven't?"

The 48-day trial heard colourful evidence about the lengths to which Merck went to promote Vioxx in Australia before it was launched in 2000. Scores of doctors were wined and dined by sales representatives at the country's most expensive restaurants, entertaining them at Sydney's Taronga Zoo and the Melbourne Aquarium.

Merck also drew up a "hit list" of doctors and academics who needed to be "neutralised" or "discredited", according to company emails, because they had criticised the drug. It paid nurses to rifle patient records for potential candidates for Vioxx, and it persuaded the world's largest medical publisher, Elsevier, to produce several issues of what appeared to be an independent scientific journal, without disclosing that it was funded by Merck. The company, which plans to appeal against yesterday's ruling, settled with thousands of US litigants in 2007, at a cost of nearly US$5bn. It made no admission of guilt, and has indicated it will fight legal action everywhere else.

In Britain, a legal aid application by potential litigants has been turned down, reportedly after Merck lobbied government ministers, including the former health minister, Ivan Lewis, who had promised in parliament to assist them.

The Federal Court judge, Christopher Jessup, said Vioxx had "about doubled the risk of heart attack" and "was not reasonably fit for the purpose of being used for the relief of arthritic pain". He said the Australian subsidiary had failed in its duty of care in not warning Mr Peterson's GP about the risks, and in the emphasis its sales representatives had placed on Vioxx's safety. But the judge ruled that Merck had not been negligent in development, scientific study and sale of the drug.

In a statement, Merck said it believed the evidence showed it had acted responsibly "right up through the decision to voluntarily withdraw the medicine in September 2004".

The British case never got off the ground because the solicitors said they could not secure legal aid. Mr Lamb said: "The legal system in this country acts in a pernicious way and stops claims being aired in court. The company should now make a global settlement to bring an end to this very sorry saga."

A Department of Health spokesperson said: "While the Government sympathises with those UK patients who have been adversely affected by Vioxx, there is no sanction the Government could impose on the company in the UK to force them to deliver a compensation deal."

Case study: 'I think Vioxx certainly contributed to my wife's death'

*On 20 January this year Raymond Eaton lost his wife to complications arising from a severe heart condition. He buried her a week later at St Mary's Church in Stody. Mr Eaton is convinced that Vioxx, the now-banned drug prescribed to alleviate arthritic pain, was to blame for her condition and premature death at the age of 74.

Mrs Eaton had suffered for more than 40 years from a debilitating form of rheumatoid arthritis, which eventually confined her to a wheelchair. When the much-hyped "blockbuster" drug Vioxx was approved she seemed a perfect candidate and was swiftly prescribed it through the local NHS in North Norfolk. But after four years on the drug, which was effective in relieving her pain, she suffered a coronary, now known to be one of the drug's serious side-effects. She survived the attack, but her health never recovered. "I think Vioxx certainly contributed to my wife's eventual death," Mr Eaton said. "During the 40 years my wife had rheumatoid arthritis, she had never ever had a problem with her heart or high blood pressure."

Mrs Eaton had spoken out against the way people in the UK had been unfairly treated by Vioxx's manufacturers, the pharmaceutical giant Merck & Co. "She didn't want anything for herself, but if it could help other people she said she would support it. It got to the point when it was completely draining her and her health," Mr Eaton said. "My wife was a wonderful person, and I miss her to bits."

The loss of his wife has galvanised Mr Eaton to pursue the case through the Cardiff-based solicitors Hugh James, which also represents more than 200 other former Vioxx users. However, he is aware that the current system is skewed in favour of corporations and the rich; he is not a very wealthy man and can't afford to lose what would be an expensive case.

News
The Banksy image in Folkestone before it was vandalised
people
Life and Style
tech

Sales of the tablet are set to fall again, say analysts

Sport
football West Brom vs Man Utd match report: Blind grabs point, but away form a problem for Van Gaal
Arts and Entertainment
Gotham is coming to UK shores this autumn
tvGotham, episode 2, review
PROMOTED VIDEO
Have you tried new the Independent Digital Edition apps?
News
ebooksAn unforgettable anthology of contemporary reportage
News
i100
Arts and Entertainment
Bloom Time: Mira Sorvino
tvMira Sorvino on leaving movie roles for 'The Intruders'
News
Brian Harvey turned up at Downing Street today demanding to speak to the Prime Minister
news

Met Police confirm there was a 'minor disturbance' and that no-one was arrested

Arts and Entertainment
George Lucas poses with a group of Star Wars-inspired Disney characters at Disney's Hollywood Studios in 2010
films

George Lucas criticises the major Hollywood film studios

Voices
Chris Grayling, Justice Secretary: 'There are pressures which we are facing but there is not a crisis'
voices

Does Chris Grayling realise what a vague concept he is dealing with?

Life and Style
A street vendor in Mexico City sells Dorilocos, which are topped with carrot, jimaca, cucumber, peanuts, pork rinds, spices and hot sauce
food + drink

Trend which requires crisps, a fork and a strong stomach is sweeping Mexico's streets

Life and Style
The charity Sands reports that 11 babies are stillborn everyday in the UK
lifeEleven babies are stillborn every day in the UK, yet no one speaks about this silent tragedy
News
Blackpool is expected to become one of the first places to introduce the Government’s controversial new Public Space Protection Orders (PSPOs)
news

Parties threaten resort's image as a family destination

Life and Style
Northern soul mecca the Wigan Casino
fashionGone are the punks, casuals, new romantics, ravers, skaters, crusties. Now all kids look the same
Life and Style
gaming

I Am Bread could actually be a challenging and nuanced title

News
Nigel Farage has backed DJ Mike Read's new Ukip song
i100
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs General

Year 5 Teacher

£80 - £140 per day: Randstad Education Leeds: Year 5 Teacher KS2 teaching job...

Software Developer

£35000 - £45000 Per Annum Pensions Scheme After 6 Months: Clearwater People So...

Systems Analyst / Business Analyst - Central London

£35000 - £37000 per annum + Benefits: Ashdown Group: Systems Analyst / Busines...

Senior Change Engineer (Network, Cisco, Juniper) £30k

£30000 - £35000 per annum + Benefits: Ampersand Consulting LLP: Senior Change ...

Day In a Page

Oscar Pistorius sentencing: The athlete's wealth and notoriety have provoked a long overdue debate on South African prisons

'They poured water on, then electrified me...'

If Oscar Pistorius is sent to jail, his experience will not be that of other inmates
James Wharton: The former Guard now fighting discrimination against gay soldiers

The former Guard now fighting discrimination against gay soldiers

Life after the Army has brought new battles for the LGBT activist James Wharton
Ebola in the US: Panic over the virus threatens to infect President Obama's midterms

Panic over Ebola threatens to infect the midterms

Just one person has died, yet November's elections may be affected by what Republicans call 'Obama's Katrina', says Rupert Cornwell
Premier League coaches join the RSC to swap the tricks of their trades

Darling, you were fabulous! But offside...

Premier League coaches are joining the RSC to learn acting skills, and in turn they will teach its actors to play football. Nick Clark finds out why
How to dress with authority: Kirsty Wark and Camila Batmanghelidjh discuss the changing role of fashion in women's workwear

How to dress with authority

Kirsty Wark and Camila Batmanghelidjh discuss the changing role of fashion in women's workwear
New book on Joy Division's Ian Curtis sheds new light on the life of the late singer

New book on Ian Curtis sheds fresh light on the life of the late singer

'Joy Division were making art... Ian was for real' says author Jon Savage
Sean Harris: A rare interview with British acting's secret weapon

Sean Harris: A rare interview with British acting's secret weapon

The Bafta-winner talks Hollywood, being branded a psycho, and how Barbra Streisand is his true inspiration
Tim Minchin, interview: The musician, comedian and world's favourite ginger is on scorching form

Tim Minchin interview

For a no-holds-barred comedian who is scathing about woolly thinking and oppressive religiosity, he is surprisingly gentle in person
Boris Johnson's boozing won't win the puritan vote

Boris's boozing won't win the puritan vote

Many of us Brits still disapprove of conspicuous consumption – it's the way we were raised, says DJ Taylor
Ash frontman Tim Wheeler reveals how he came to terms with his father's dementia

Tim Wheeler: Alzheimer's, memories and my dad

Wheeler's dad suffered from Alzheimer's for three years. When he died, there was only one way the Ash frontman knew how to respond: with a heartfelt solo album
Hugh Bonneville & Peter James: 'Peter loves his classic cars; I've always pootled along fine with a Mini Metro. I think I lack his panache'

How We Met: Hugh Bonneville & Peter James

'Peter loves his classic cars; I've always pootled along fine with a Mini Metro. I think I lack his panache'
Bill Granger recipes: Our chef's heavenly crab dishes don't need hours of preparation

Bill Granger's heavenly crab recipes

Scared off by the strain of shelling a crab? Let a fishmonger do the hard work so you can focus on getting the flavours right
Radamel Falcao: How faith and love drive the Colombian to glory

Radamel Falcao: How faith and love drive the Colombian to glory

After a remarkable conversion from reckless defender to prolific striker, Monaco's ace says he wants to make his loan deal at Old Trafford permanent
Terry Venables: Premier League managers must not be allowed to dictate who plays and who does not play for England

Terry Venables column

Premier League managers must not be allowed to dictate who plays and who does not play for England
The Inside Word: Brendan Rodgers looks to the future while Roy Hodgson is ghost of seasons past

Michael Calvin's Inside Word

Brendan Rodgers looks to the future while Roy Hodgson is ghost of seasons past